Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 17/20 | 0.71 |
| ▸ | ACHE | P22303 | 1/20 | 0.68 |
| ▸ | RAD52 | P43351 | 1/20 | 0.68 |
| ▸ | HRH2 | P25021 | 6/20 | 0.68 |
| ▸ | HRH1 | P35367 | 6/20 | 0.68 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1715391 | 0.91 | HRH3 (0.84) | HRH3HRH2HRH1CACNA1B | |
| SCHEMBL5623066 | 0.88 | HRH3 (0.79) | HRH3HRH2HRH1CACNA1B | |
| SCHEMBL14393458 | 0.86 | HRH3 (0.88) | HRH3HRH2HRH1 | |
| SCHEMBL1714440 | 0.86 | HRH3 (0.88) | HRH3HRH2HRH1CACNA1B | |
| Hydrochloric Acid SCHEMBL1714618 | 0.85 | HRH3 (0.86) | HRH3HRH2HRH1 | |
| SCHEMBL7295095 | 0.85 | HRH3 (0.75) | HRH3HRH2HRH1 | |
| SCHEMBL491845 | 0.84 | HRH3 (0.97) | HRH3HRH2HRH1CACNA1B | |
| SCHEMBL24324260 | 0.84 | HRH3 (0.73) | HRH3HRH2HRH1 | |
| SCHEMBL491825 | 0.83 | HRH3 (1.00) | HRH3ACHERAD52HRH2HRH1 | |
| SCHEMBL492096 | 0.83 | HRH3 (1.00) | HRH3ACHERAD52HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1481966-B1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1481966-A1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | SLC7A1, NAT1, NACA | HRH3 395/4885ACHE 4870/4885RAD52 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.